Linde Equity Method Investments decreased by 5.4% to $2.02B in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 5.4%, from $2.13B to $2.02B. Over 5 years (FY 2020 to FY 2025), Equity Method Investments shows relatively stable performance with a -0.5% CAGR.
An increase indicates strategic expansion through partnerships or joint ventures, while a decrease may signal divestments or impairment.
These are investments in entities where the company exercises significant influence but does not have full control. The...
Varies significantly based on corporate strategy; common in healthcare companies that partner with biotech startups or specialized diagnostic firms.
equity_method_investments| Q4 '21 | Q4 '22 | Q4 '23 | Q4 '24 | Q4 '25 | |
|---|---|---|---|---|---|
| Value | $2.62B | $2.35B | $2.19B | $2.13B | $2.02B |
| QoQ Change | — | -10.3% | -6.8% | -2.7% | -5.4% |
| YoY Change | — | -10.3% | -6.8% | -2.7% | -5.4% |